These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 36472728)

  • 1. Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases.
    Brown G; Belkoff L; Hafron JM; Saltzstein DR; Potdar R; Bhaumik A; Phillips J; McGowan T; Shore ND
    Target Oncol; 2023 Jan; 18(1):95-103. PubMed ID: 36472728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).
    Shore N; Hafron J; Saltzstein D; Brown G; Belkoff L; Aggarwal P; Phillips J; Bhaumik A; McGowan T
    J Urol; 2024 Nov; 212(5):682-691. PubMed ID: 39088398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
    Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
    Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer.
    Spratt DE; George DJ; Shore ND; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown BA; Lu S; Fallick M; Hanson S; Tombal BF
    JAMA Oncol; 2024 May; 10(5):594-602. PubMed ID: 38451492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.
    Shore ND; Saad F; Cookson MS; George DJ; Saltzstein DR; Tutrone R; Akaza H; Bossi A; van Veenhuyzen DF; Selby B; Fan X; Kang V; Walling J; Tombal B;
    N Engl J Med; 2020 Jun; 382(23):2187-2196. PubMed ID: 32469183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer.
    De La Cerda J; Dunshee C; Gervasi L; Sieber P; Belkoff L; Tutrone R; Lu S; Gatoulis SC; Brown B; Migoya E; Shore N
    Target Oncol; 2023 May; 18(3):383-390. PubMed ID: 37060432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
    Garnick MB; Mottet N
    BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relugolix: A Review in Advanced Prostate Cancer.
    Shirley M
    Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
    George DJ; Dearnaley DP
    Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer.
    Lee LS; Sim AYL; Ong CW; Yang X; Ng CCY; Liu W; Rajasegaran V; Lim AMS; Aslim EJ; Ngo NT; Khor LY; Kanesvaran R; Allen JCJ; Tay KJ; Yuen JSP; Chong TW; Ho SSH; Teh BT; Chua MLK
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):741-748. PubMed ID: 35091711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer.
    Shore ND; Guerrero S; Sanahuja RM; Gambús G; Parente A
    Clin Ther; 2019 Mar; 41(3):412-425. PubMed ID: 30929678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
    Maluf FC; Schutz FA; Cronemberger EH; Luz MA; Martins SPS; Muniz DQB; Bastos DA; Cárcano FM; Smaletz O; Soares A; Peixoto FA; Gomes AJ; Cruz FM; Franke FA; Herchenhorn D; Dos Santos TM; Fabricio VC; Gidekel R; Werutsky G; de Jesus RG; Souza VC; Fay AP
    Eur J Cancer; 2021 Oct; 158():63-71. PubMed ID: 34655838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
    George DJ; Saad F; Cookson MS; Saltzstein DR; Tutrone R; Bossi A; Brown B; Selby B; Lu S; Buckley D; Tombal B; Shore ND
    Clin Genitourin Cancer; 2023 Jun; 21(3):383-392.e2. PubMed ID: 37062659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer.
    Shore ND; Mehlhaff BA; Cookson MS; Saltzstein DR; Tutrone R; Brown B; Lu S; Fallick M; Hanson S; Saad F
    Adv Ther; 2023 Nov; 40(11):4919-4927. PubMed ID: 37713020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
    Aggarwal R; Heller G; Hillman DW; Xiao H; Picus J; Taplin ME; Dorff T; Appleman L; Weckstein D; Patnaik A; Bryce A; Shevrin D; Mohler J; Anderson D; Rao A; Tagawa S; Tan A; Halabi S; Dooley K; O'Brien P; Chen R; Ryan CJ; Eggener SE; Morris MJ;
    J Clin Oncol; 2024 Apr; 42(10):1114-1123. PubMed ID: 38261983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.
    Tombal B; Collins S; Morgans AK; Hunsche E; Brown B; Zhu E; Bossi A; Shore N
    Eur Urol; 2023 Dec; 84(6):579-587. PubMed ID: 37833178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relugolix in the management of prostate cancer.
    Sahu KK; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer.
    Shore ND; Sutton J
    Future Oncol; 2022 Jul; 18(21):2575-2584. PubMed ID: 35587650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
    Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
    Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.